[1] RaoKV,SrinivasLD,RavikumarP,YesupadamP,PrabhakarG., 2006.A note on the estimation of moxifloxacin in bulk and pharmaceutical formulations by precipitation reagents,J Chem 3 5 -8
[2] KowalskiRP,DhaliwalDK,KarenchakLM,RomanowskiEG,MahFS,RitterbandDC,GordonYJ, 2003.Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates,Am J Ophthalmol 136 500 -5
[3] PestovaE,MillichapJJ,NoskinGA,PetersonLR, 2000.Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones,American journal of ophthalmology 45 583 -90
[4] BalfourJA,WisemanLR, 1999., 57 363 -73
[5] WilsonR,AllegraL,HuchonG,IzquierdoJL,JonesP,SchabergT,SagnierPP, 2004.Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis,Chest 125 953 -64
[6] SeverPS,DahlöfB,PoulterNR,WedelH,BeeversG,CaulfieldM,CollinsR,KjeldsenSE,KristinssonA,McInnesGT,MehlsenJ, 2003.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial,Lancet 361 1149 -58
[7] ColhounHM,BetteridgeDJ,DurringtonPN, 2004.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial,Lancet 364 685 -96
[8] BaigentC,KeechA,Kearney P M , Blackwell L,BuckG,PollicinoC., 2005.Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90 056 participants in 14 randomised trials of statins,Lancet 366 1267 -78
[9] ChongPH,SeegerJD,FranklinC, 2001.Clinically relevant differences between the statins: implications for therapeutic selection,Am J Med 111 390 -400
[10] SibilaO,RestrepoMI,AnzuetoA, 2013.What is the best antimicrobial treatment for severe community-acquired pneumonia (including the role of steroids and statins and other immunomodulatory agents,Clin Infect Dis 27 133 -47
[11] DoblerCC,WongKK,MarksGB, 2009.Associations between statins and COPD: a systematic review,BMC Pulm Med 9 32 -
[12] KwakB,MulhauptF,MyitS, 2000.Statins as a newly recognized type of immunomodulator,Nat Med 6 1399 -
[13] Laban-DjurdjevićA,Jelikić-StankovM,DjurdjevićP, 2006.Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma,J Chromatogr B 844 104 -11
[14] UluST, 2007.High-performance liquid chromatography assay for moxifloxacin: pharmacokinetics in human plasma,J Pharm Biomed Anal 43 320 -4
[15] DewaniAP,BarikBB,KanungoSK,WattyaniBR,ChandewarAV, 2011.Development and validation of RP-HPLC method for the determination of moxifloxacin in presence of its degradation products,American-Eurasian Journal of Scientific Research 6 192 -200
[16] De SmetJ,BousseryK,ColpaertK,De SutterP,De PaepeP,DecruyenaereJ,Van Bocxlaer, 2009.Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma,J Chromatogr B 877 961 -7
[17] SrinivasN,NarasuL,ShankarBP,MullangiR, 2008.Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study,Biomed Chromatogr 22 1288 -95